Neuropace/$NPCE
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Ticker
$NPCE
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
195
ISIN
US6412881053
Website
Neuropace Metrics
BasicAdvanced
$334M
-
-$0.83
2.05
-
Price and volume
Market cap
$334M
Beta
2.05
52-week high
$18.98
52-week low
$5.45
Average daily volume
391K
Financial strength
Current ratio
6.628
Quick ratio
5.555
Long term debt to equity
293.498
Total debt to equity
301.422
Interest coverage (TTM)
-2.22%
Profitability
EBITDA (TTM)
-19.062
Gross margin (TTM)
74.83%
Net profit margin (TTM)
-29.42%
Operating margin (TTM)
-22.86%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-11.52%
Return on equity (TTM)
-128.49%
Valuation
Price to revenue (TTM)
3.61
Price to book
13.72
Price to tangible book (TTM)
13.72
Price to free cash flow (TTM)
-16.775
Free cash flow yield (TTM)
-5.96%
Free cash flow per share (TTM)
-60.62%
Growth
Revenue change (TTM)
22.05%
Earnings per share change (TTM)
-30.08%
3-year revenue growth (CAGR)
22.97%
3-year earnings per share growth (CAGR)
-21.48%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Bulls say / Bears say
NeuroPace reported record quarterly revenue of $22.5 million in Q1 2025, a 24% year-over-year increase, driven by growing demand for its RNS System. (stocktitan.net)
The company raised its full-year 2025 revenue guidance to $93–97 million, indicating confidence in sustained growth. (stocktitan.net)
Analysts have set a consensus target price of $15.00 for NPCE, reflecting positive expectations for the stock's performance. (etfdailynews.com)
Preliminary results from the NAUTILUS study showed that the primary effectiveness endpoint did not reach statistical significance in the overall population, potentially impacting future adoption of the RNS System. (stocktitan.net)
The company reported a net loss of $6.6 million in Q1 2025, despite revenue growth, indicating ongoing profitability challenges. (stocktitan.net)
NeuroPace's stock experienced a significant decline of approximately 28% following the release of the NAUTILUS study results, reflecting investor concerns. (newsheater.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Neuropace News
AllArticlesVideos
NeuroPace Announces Strategic CFO Transition
GlobeNewsWire·2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
GlobeNewsWire·3 weeks ago
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $334M as of July 11, 2025.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of July 11, 2025.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 2.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.